Abstract 5488
Background
In the course of tumor growth, the cells that are far from the blood vessel are exposed to hypoxic conditions. As part of this process transcription factors (TFs) of the Snail family (Snail, Slug, Twist1, and Zeb1) are activated launching the epithelial-mesenchymal transition (EMT) program. Snail family factors are the most studied as stimulators of EMT, promoting tumor progression, migration and invasion of tumor cells. The aim of our research is to study adaptive mechanisms of human breast cancer (BC) cells to hypoxia and the analysis of the role of the TF Snail in this process.
Methods
We used human BC cells MCF-7, MDA-MB-231 and HBL-100 which were cultured in standard DMEM containing 10% fetal calf serum at 37oC and 5% СО2. For hypoxia modeling, the cells were cultured in a CO2-incubator maintaining O2 concentration at 1%.
Results
Knockdown of the Snail by small interfering RNA (siRNA) leads to increased sensitivity of breast cancer cells to hypoxia, due to increased blocking of cells in the S-phase of cell cycle. Cells were more resistant to hypoxia at a lower density, where Snail expression was increased, but further hyperexpression of Snail had not lead to increased resistance to hypoxia. Knockdown of Snail leads to an compensatory increase of Slug`s expression, while the knockdown of Twist1 and Zeb1 leads to decreased Slug expression. Knockdown of Twist1 decreases cell proliferation both in hypoxia and normoxia, through activation of cell cycle inhibitor p21WAF1, specifically in the G2/M phase, in p53-wild type HBL-100 cells. We used a chemical inhibitor of p53-Snail interaction GN25, to examine if blocking of this interaction could lead to increased sensitivity in hypoxia. We have shown that this compound has a greater cytotoxic effect in normoxia than hypoxia, due to increased Snail activity.
Conclusions
Modulation of Snail-associated signaling pathways is a perspective target for increase of cancer cell tolerance to chronic hypoxia, and inhibition of metastatic process in breast cancer cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Grant no. 14.W03.31.0020 between the Ministry of Science and Education of the Russian Federation and Institute of Gene Biology, Russian Academy of Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3993 - Prophylaxis with Lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: results from the German NIS NADENS
Presenter: Marion Kiechle
Session: Poster Display session 1
Resources:
Abstract
3471 - Randomized phase 2 trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients.
Presenter: Florian Clatot
Session: Poster Display session 1
Resources:
Abstract
1327 - Simultaneous intravenous fluid infusion to prevent oxaliplatin infusion-related venous pain
Presenter: Stefan Van Ravensteijn
Session: Poster Display session 1
Resources:
Abstract
5004 - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project.
Presenter: Enrique Aranda Aguilar
Session: Poster Display session 1
Resources:
Abstract
2222 - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response.
Presenter: Manuel Cobo Dols
Session: Poster Display session 1
Resources:
Abstract
5556 - Consensus on strategies in the management of opioid-induced constipation in cancer patients
Presenter: Regina Girones Sarrio
Session: Poster Display session 1
Resources:
Abstract
3913 - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Presenter: Yanni Lou
Session: Poster Display session 1
Resources:
Abstract
2208 - A prospective study about the complementary medicine among patients with cancers
Presenter: Wala Ben Kridis
Session: Poster Display session 1
Resources:
Abstract
1082 - Prevalence and management of Potentially Inappropriate Medication use and Potential Omissions in Medication in older cancer patients - the PIM POM study
Presenter: Fianne van Loveren
Session: Poster Display session 1
Resources:
Abstract
1701 - Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer : A randomized controlled trial
Presenter: Wonyoung Choi
Session: Poster Display session 1
Resources:
Abstract